Schroder Investment Management Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Schroder Investment Management Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-535,968	Closed	-$4.05M	–	1153
2025 Q3	$4.05M	Buy	+535,968	New	+$4.46M	﹤0.01%	806
2025 Q2	–	Sell	-522,657	Closed	-$4.11M	–	1166
2025 Q1	$4.11M	Hold	522,657	–	–	﹤0.01%	802
2024 Q4	$3.94M	Buy	522,657 +438,887	+524%	+$3.33M	﹤0.01%	815
2024 Q3	$638K	Buy	+83,770	New	+$637K	﹤0.01%	1081
2020 Q1	–	Sell	-55,420	Closed	-$191K	–	1306
2019 Q4	$191K	Buy	+55,420	New	+$139K	﹤0.01%	1166

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Schroder Investment Management Group's BCRX Position: Q4 2025 in Review

Schroder Investment Management Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 535,968 shares — an estimated $4.05M sold.

Schroder Investment Management Group first reported a position in BCRX in Q4 2019 and held it in 5 quarters. The position peaked at $4.11M in Q1 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Schroder Investment Management Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Schroder Investment Management Group sold 535,968 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $4.05M.
Schroder Investment Management Group first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 5 quarters.
Schroder Investment Management Group's BioCryst Pharmaceuticals position peaked at $4.11M in Q1 2025.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.